<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Zalicus Inc News Release</title><link>http://phx.corporate-ir.net/Phoenix.zhtml?c=148036&amp;p=irol-news</link><description>A Collection of Zalicus Inc News Release</description><language>en-us</language><category>Uncategorized</category><lastBuildDate>Sat, 18 May 2013 05:12:37 GMT</lastBuildDate><item><title>Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=148036&amp;p=RssLanding&amp;cat=news&amp;id=1818165</link><description><![CDATA[Preclinical Data on Z160 and Z944 Presented at the American Pain
      Society 2013 Annual Meeting
    
    CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 10, 2013--
      Zalicus
      Inc. (Nasdaq Capital Market: ZLCS) today announced that preclinical
      data highlighting its novel, oral ion channel programs for the treatment
      of pain including Z160, an N-type calcium channel blocker and Z944, a
      T-type calcium channel blocker were presented at the 32nd Annual
      Scientific Meeting of the American Pain Society taking place May 8-11,
      2013 in New Orleans, LA.
    

      “These data demonstrate the significant progress we have made in
      validating the activit...]]></description><category>Uncategorized</category><guid isPermaLink="false">1818165_NEWS</guid><pubDate>Fri, 10 May 2013 12:45:14 GMT</pubDate></item><item><title>Zalicus Secures New $25 Million Funding Commitment from Lincoln Park Capital</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=148036&amp;p=RssLanding&amp;cat=news&amp;id=1816959</link><description><![CDATA[CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 8, 2013--
      Zalicus
      Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that
      discovers and develops novel treatments for patients suffering from
      pain, today announced that it has entered into a stock purchase
      agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) an
      institutional investor. Under the terms of the agreement, Zalicus has
      the right to sell up to $25,000,000 in shares of its common stock to
      Lincoln Park subject to certain limitations and conditions set forth in
      the purchase agreement.
    

      Upon executing the agreement, Lincoln Park made an initial pur...]]></description><category>Uncategorized</category><guid isPermaLink="false">1816959_NEWS</guid><pubDate>Wed, 08 May 2013 12:30:47 GMT</pubDate></item><item><title>Zalicus Reports Financial Results for the First Quarter 2013</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=148036&amp;p=RssLanding&amp;cat=news&amp;id=1814230</link><description><![CDATA[CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 2, 2013--
      Zalicus
      Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that
      discovers and develops novel treatments for patients suffering from
      pain, today reported financial results for the first quarter ended March
      31, 2013.
    

      “This has been a productive quarter for Zalicus as evidenced by the
      extension of our Novartis collaboration and the bolstering of our ion
      channel intellectual property estate to broaden and extend exclusivity
      for our ion channel programs Z160 and Z944,” commented Mark H.N.
      Corrigan, MD, President and CEO of Zalicus. “Our primary focus is on
...]]></description><category>Uncategorized</category><guid isPermaLink="false">1814230_NEWS</guid><pubDate>Thu, 02 May 2013 11:30:47 GMT</pubDate></item><item><title>Zalicus Granted Key Formulation Patent for Z160</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=148036&amp;p=RssLanding&amp;cat=news&amp;id=1802323</link><description><![CDATA[Extends Z160 Patent Coverage through March 2032
    
    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 2, 2013--
      Zalicus
      Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that
      discovers and develops novel treatments for patients suffering from
      pain, today announced that it has been granted a patent by the U.S.
      Patent and Trademark office (USPTO) covering novel formulations of its
      product candidate Z160. United States patent number 8,409,560, entitled
      “Solid Dispersion Formulations and Methods of Use Thereof,” provides
      broad coverage for a range of novel Z160 pharmaceutical compositions and
      methods of using these composit...]]></description><category>Uncategorized</category><guid isPermaLink="false">1802323_NEWS</guid><pubDate>Tue, 02 Apr 2013 12:01:02 GMT</pubDate></item><item><title>Zalicus Presents Data Demonstrating Advantages of State-Dependent Ion Channel Screening</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=148036&amp;p=RssLanding&amp;cat=news&amp;id=1797731</link><description><![CDATA[
      Utility of Inactivation State Screening for the Identification of
      Novel Pain Therapies Presented at RSC/SCI Symposium on Ion Channels as
      Therapeutic Targets Conference
    

    
    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 19, 2013--
      Zalicus
      Inc. (Nasdaq Global Market: ZLCS) today announced that preclinical
      data showing the advantages of applying Zalicus’s state dependent
      screening approach to identify novel calcium channel blockers for the
      treatment of pain was presented on March 18 at the 4th Annual RSC/SCI
      Symposium on Ion Channels as Therapeutic Targets Conference taking place
      from March 18-19, 2013 in Cambridge, ...]]></description><category>Uncategorized</category><guid isPermaLink="false">1797731_NEWS</guid><pubDate>Tue, 19 Mar 2013 12:00:40 GMT</pubDate></item><item><title>Zalicus Reports Financial Results for the Fourth Quarter and Year End 2012</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=148036&amp;p=RssLanding&amp;cat=news&amp;id=1792806</link><description><![CDATA[
      Provides Key Goals for 2013
    
    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2013--
      Zalicus
      Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that
      discovers and develops novel treatments for patients suffering from
      pain, today reported financial results for the fourth quarter and year
      ended December 31, 2012.
    

      “We are focused on advancing the development of our ion channel
      programs, including Z160, our first-in-class, oral N-type calcium
      channel blocker for the treatment of chronic neuropathic pain and Z944,
      a novel oral T-type calcium channel blocker,” commented Mark H.N.
      Corrigan, MD, Pre...]]></description><category>Uncategorized</category><guid isPermaLink="false">1792806_NEWS</guid><pubDate>Wed, 06 Mar 2013 12:30:50 GMT</pubDate></item><item><title>Zalicus Granted Composition-of-Matter Patent for Z944</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=148036&amp;p=RssLanding&amp;cat=news&amp;id=1786715</link><description><![CDATA[
      Key Patent Provides Broad Coverage for Z944 through April 2029
    
    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 20, 2013--
      Zalicus
      Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that
      discovers and develops novel treatments for patients suffering from
      pain, today announced that it has been granted a patent by the U.S.
      Patent and Trademark office (USPTO) covering its product candidate Z944.
      United States patent number 8,377,968 entitled “N-Piperidinyl Acetamide
      Derivatives as Calcium Channel Blockers” provides broad coverage for
      Z944 including compositions of matter and certain therapeutic methods of
      use t...]]></description><category>Uncategorized</category><guid isPermaLink="false">1786715_NEWS</guid><pubDate>Wed, 20 Feb 2013 13:00:38 GMT</pubDate></item><item><title>Zalicus to Present at the 2013 BIO CEO &amp; Investor Conference</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=148036&amp;p=RssLanding&amp;cat=news&amp;id=1781463</link><description><![CDATA[    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2013--
      Zalicus
      Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and
      develops novel treatments for patients suffering from pain, today
      announced that Zalicus management will present at the 2013 BIO CEO &amp;
      Investor Conference at 9:00 p.m. ET on Tuesday, February 12, 2013 at the
      Waldorf Astoria in New York. Interested parties may access a live
      webcast of the presentation by visiting the Zalicus website at www.zalicus.com.
      The webcast will be archived on the Zalicus website following the event.
    

      About Zalicus
    

      Zalicus Inc. (Nasdaq: ZLCS) is a biopha...]]></description><category>Uncategorized</category><guid isPermaLink="false">1781463_NEWS</guid><pubDate>Tue, 05 Feb 2013 13:34:23 GMT</pubDate></item><item><title>Zalicus Initiates the Second of Two Phase 2a Studies with Z160</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=148036&amp;p=RssLanding&amp;cat=news&amp;id=1770779</link><description><![CDATA[
      - Highlights 2012 Accomplishments -
    
    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2013--
      Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers
      and develops novel treatments for patients suffering from pain, today
      announced that it has initiated the second of two Phase 2a clinical
      studies with Z160, its first-in-class, oral, state-dependent, selective
      N-type (Cav2.2) calcium channel blocker for the potential treatment of
      chronic neuropathic pain. The Company also provided an overview of 2012
      accomplishments.
    

      Z160 is designed to selectively target neuronal pain signaling by
      modulating neuro...]]></description><category>Uncategorized</category><guid isPermaLink="false">1770779_NEWS</guid><pubDate>Thu, 03 Jan 2013 12:30:23 GMT</pubDate></item><item><title>Zalicus to Present at the Oppenheimer 23rd Annual Healthcare Conference</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=148036&amp;p=RssLanding&amp;cat=news&amp;id=1764757</link><description><![CDATA[    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 5, 2012--
      Zalicus
      Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and
      develops novel treatments for patients suffering from pain, today
      announced that Zalicus management will present at the Oppenheimer 23rd
      Annual Healthcare Conference at 1:00 p.m. ET on Wednesday December 12,
      2012 at the Waldorf Astoria in New York. Interested parties may access a
      live webcast of the presentation by visiting the Zalicus website at www.zalicus.com.
      The webcast will be archived on the Zalicus website following the event.
    

      About Zalicus
    

      Zalicus Inc. (Nasdaq: ZLCS) is ...]]></description><category>Uncategorized</category><guid isPermaLink="false">1764757_NEWS</guid><pubDate>Wed, 05 Dec 2012 21:01:10 GMT</pubDate></item></channel></rss>